Bogle Investment Management’s Anika Therapeutics ANIK Stock Holding History

Bogle Investment Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-59,808	Closed	-$3.1M	–	274
2019 Q4	$3.1M	Buy	+59,808	New	+$3.47M	0.29%	110
2018 Q1	–	Sell	-5,200	Closed	-$280K	–	306
2017 Q4	$280K	Buy	+5,200	New	+$288K	0.02%	259
2016 Q4	–	Sell	-22,629	Closed	-$1.08M	–	328
2016 Q3	$1.08M	Sell	22,629 -82,340	-78%	-$4.07M	0.08%	249
2016 Q2	$5.63M	Sell	104,969 -6,000	-5%	-$283K	0.39%	95
2016 Q1	$4.96M	Buy	110,969 +60,087	+118%	+$2.44M	0.33%	101
2015 Q4	$1.94M	Buy	+50,882	New	+$1.95M	0.14%	193
2015 Q1	–	Sell	-9,600	Closed	-$391K	–	353
2014 Q4	$391K	Sell	9,600 -48,631	-84%	-$1.9M	0.03%	309
2014 Q3	$2.13M	Sell	58,231 -226,162	-80%	-$9.77M	0.14%	165
2014 Q2	$13.2M	Hold	284,393	–	–	0.88%	25
2014 Q1	$11.7M	Buy	284,393 +79,976	+39%	+$2.97M	0.8%	25
2013 Q4	$7.8M	Buy	204,417 +25,650	+14%	+$791K	0.66%	58
2013 Q3	$4.27M	Buy	178,767 +155,499	+668%	+$3.49M	0.43%	89
2013 Q2	$395K	Buy	+23,268	New	+$336K	0.05%	249

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bogle Investment Management's ANIK Position: Q1 2020 in Review

Bogle Investment Management sold out of Anika Therapeutics (ANIK) in Q1 2020, closing a stake of 59,808 shares — an estimated $3.1M sold.

Bogle Investment Management first reported a position in ANIK in Q2 2013 and held it in 13 quarters. The position peaked at $13.2M in Q2 2014. 163 funds tracked by Wall St. Rank hold ANIK as of Q1 2020.

Bogle Investment Management reported no remaining Anika Therapeutics position as of Q1 2020 after selling out during the quarter.
Bogle Investment Management sold 59,808 Anika Therapeutics shares in Q1 2020, an estimated $3.1M.
Bogle Investment Management first reported a position in Anika Therapeutics in Q2 2013 and held it in 13 quarters.
Bogle Investment Management's Anika Therapeutics position peaked at $13.2M in Q2 2014.
163 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2020.

Based on Bogle Investment Management's 13F filing for Q1 2020, filed 13 May 2020.